Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sexual Function in Men Treated for BPH with Duodart
NCT01777269Phase 4Completed
- Sponsor
- GSK
- Start
- Feb 2013
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 4, randomised, double-blind trial of alpha blocker + 5-alpha reductase inhibitor in benign prostatic hyperplasia (BPH) (2 arms), sponsored by GSK. Primary endpoint: Change from Baseline in Total Score from the Full Men's Sexual Health Questionnaire at 12 months. Started Feb 2013; status: completed.
02
Drugs
alpha blocker + 5-alpha reductase inhibitor
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT01777269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01777269.